1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Coloplast A/S

Coloplast A/S

COLO-B.CO
Coloplast A/SDK flagNASDAQ Copenhagen
401.90
DKK
+0.90
- -
90.57BMarket Cap
Coloplast A/S
COLO-B.CO
(NASDAQ Copenhagen)

Recent

price

401.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
41.41
44.77
48.44
52.44
55.25
58.96
65.83
69.35
73.18
77.52
84.5
87.22
91.29
106.25
113.74
120.19
123.71
Revenue per Share
4.15
5.84
8.66
10.44
12.87
11.34
4.25
14.85
17.89
18.12
18.24
19.74
22.67
22.15
22.21
22.46
18.09
Basic EPS, GAAP
5.91
6.87
9.31
10.99
12.8
12.41
12.87
11.24
12.09
17.4
17.53
18.01
15.62
18.65
13.86
6.31
21.97
Free Cash Flow per Basic Share
1.21
1.41
2.01
2.79
7.01
11.01
12
12.52
13.5
15.49
16.01
16.99
18
19.02
19.72
20.99
22.01
Dividend per Share
13.61
16.31
18.92
24.93
25.4
23.36
14.56
15.12
17.7
20.16
21.63
23.31
26.42
26.36
68.99
69.45
75.65
Book Value per Share
9.8
7.91
12.62
20.63
24.94
22.78
15.12
17.34
17.23
18.38
20.78
23.72
21.23
-68.12
-64.79
-55.09
-59.79
Tangible Book Value per Share
213
213
210
210
211
211
211
212
212
212
212
213
213
212
215
225
225
Basic Weighted Avg Shares
8,820
9,537
10,172
11,023
11,635
12,428
13,909
14,681
15,528
16,449
17,939
18,544
19,426
22,579
24,500
27,030
27,867
Sales/Revenue/Turnover
16.72
21.79
25.37
29.53
31.56
33.37
32.6
33.01
32.35
30.95
30.97
31.57
32.71
30.6
27.94
26.96
26.99
Operating Margin (%)
549
589
527
501
488
426
485
528
611
625
651
851
792
930
1,069
1,290
1,350
Depreciation Expense
883
1,243
1,819
2,194
2,711
2,390
899
3,143
3,797
3,845
3,873
4,197
4,825
4,706
4,783
5,052
4,075
Net Income, GAAP
27.09
25.75
25.94
25.73
25.21
25.1
27.79
23
23.29
23.24
22.97
23.22
22.59
23.19
20.61
21
34.33
Effective Tax Rate (%)
10.01
13.03
17.88
19.9
23.3
19.23
6.46
21.41
24.45
23.38
21.59
22.63
24.84
20.84
19.52
18.69
14.62
Profit Margin (%)
1,382
1,295
2,878
2,261
3,100
2,518
1,187
855
769
882
1,417
1,510
680
1,436
-6,374
240
3
Working Capital
2,256
1,551
1,996
- -
- -
- -
- -
1
98
91
134
430
449
16,855
12,222
17,291
17,276
LT Debt
2,850
3,452
4,452
6,042
6,769
6,283
4,706
5,068
5,952
6,418
6,913
7,406
8,168
8,292
17,299
17,942
16,448
Total Equity
18.95
27.44
30.04
32.08
35.09
42.72
55.66
72.64
57.36
46.98
48.36
46.99
45.18
26.55
15.7
13.99
11.68
Return on Invested Capital (%)
19.87
28.24
34.55
35.89
45.8
45.66
22.03
95.47
88.17
71.04
67.79
67.5
64.12
29.57
18.01
15.63
11.63
Return on Capital (%)
35.87
39.01
48.86
47.62
51.19
46.52
22.47
100.16
109.19
95.72
87.32
87.91
91.23
83.86
46.75
33.15
23.36
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'25
ST Debt
7,446
6,935
6,939
LT Borrowings
16,562
16,565
16,564
LT Finance Leases
749
764
712
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
225
225
225
Market Capitalization
176,764
162,768
135,520

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'25
Total Current Assets
10,366
10,467
10,556
Cash, Cash Equivalents & STI
906
729
726
Accounts Receivable, Net
4,609
4,752
4,789
Inventories
3,673
3,797
3,777
Total Current Liabilities
12,765
10,967
10,553
Payables & Accruals
- -
- -
- -
ST Debt
7,446
6,935
6,939
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.68%
26.26%
3.72%
Free Cash Flow
-2.42%
-13.63%
-52.43%
Net Income, GAAP
23.82%
5.62%
5.62%
Sales/Revenue/Turnover
8.14%
8.64%
10.33%
Total Cash Common Dividend
7.41%
6.82%
11.14%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,606
6,586
6,885
6,953
27,030
2025
7,084
6,930
6,958
7,043
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.4
5.57
5.67
- -
22.46
2025
-4.31
4.05
3.57
6.21
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16.01
- -
5
- -
20.99
2025
- -
- -
5
18.03
- -
Similar Companies
Sugentech Inc. (253840.KQ)
General Biologicals Corporation (4117.TWO)
United American Healthcare Corporation (UAHC)
Dynamic Medical Technologies Inc. (4138.TWO)
Clarity Pharmaceuticals Ltd (CU6.AX)
ENvue Medical, Inc. (FEED)
Business
Coloplast A/S develops manufactures and markets medical devices and services for intimate healthcare needs including ostomy urology continence wound care bowel care voice and respiratory care and interventional urology; its core products encompass ostomy bags and accessories such as Sensura Mio pouches baseplates and convexity solutions; intermittent catheters including the Luja catheter; bowel management systems for transanal irrigation; voice and respiratory care devices for laryngectomy and tracheostomy patients; advanced wound dressings and biologics through subsidiaries like Kerecis; and interventional urology solutions for men's health with upcoming Intibia for women's health pending FDA approval. Founded in 1957 and headquartered in Humlebæk Denmark the company employs over 14000 people operates sales in more than 50 countries with production facilities in Denmark Hungary France China and the US and serves hospitals institutions wholesalers retailers and direct-to-consumer channels primarily in Europe North America and emerging markets. Recent developments include the presentation of its Impact4 five-year strategy in September 2025 targeting 7-8% organic revenue growth through 2030 solidification of chronic care leadership with new ostomy solutions Luja catheters US bowel care reimbursement from October 2025 and Intibia launch in 2026/27; reorganization into Chronic Care and Acute Care business units announced in August 2025; ongoing integration of the 2021 Atos Medical acquisition finalizing in 2025/26 with DKK 100 million synergies; completion of prior acquisitions like Comfort Medical Hope Medical and Rocky Medical Supply; and Global Operations Plan 7 for gross margin and cash flow improvements.